Research Topics
Genomes and GenesSpecies | Joaquim J FerreiraSummaryCountry: Portugal Publications
| Collaborators
|
Detail Information
Publications
Skin cancer and Parkinson's diseaseJoaquim J Ferreira
Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
Mov Disord 25:139-48. 2010..Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening...
Skin cancers and precancerous lesions in Parkinson's disease patientsJoaquim Ferreira
Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
Mov Disord 22:1471-5. 2007..The frequency of actinic keratosis in PD patients and the associated risk to develop melanoma recommends its screening in future epidemiological studies...- The management of cervical dystoniaJoaquim J Ferreira
Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649 028 Lisboa, Portugal
Expert Opin Pharmacother 8:129-40. 2007.... - [Botulinum toxin for the treatment of pain syndromes]Joaquim J Ferreira
Unidade Neurológica de Investigação Clínica, Instituto de Medicina Molecular, Lisboa
Acta Reumatol Port 31:49-62. 2006..This does not exclude the subsequent need to conduct pragmatic trials to evaluate the effectiveness of BoNT in conditions where the improvement of pain or any associated clinical sign or symptom may be of clinical relevance... - Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteersJ J Ferreira
Neurological Clinical Research Unit, Lisbon School of Medicine, Lisbon, Portugal
Eur J Neurol 13:209-14. 2006..7%). Abnormal daytime somnolence and poor sleep quality at night are more frequent in PD patients than in normals. However, SA are reported in both groups, although less frequently in the normals during activities that requires attention... - A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's diseaseJoaquim J Ferreira
Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon, Portugal
CNS Neurosci Ther 16:337-47. 2010..The results of this study show that nebicapone 150 mg is efficacious for the treatment of motor fluctuations in PD patients. However, the risk of increasing liver transaminases and its clinically relevance deserves further evaluation... - What motivates Parkinson's disease patients to enter clinical trials?Anabela Valadas
Department of Neurosciences, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
Parkinsonism Relat Disord 17:667-71. 2011..Limited data is available regarding motivations and concerns of Parkinson's disease (PD) patients when participating in clinical trials (CTs). Knowledge of these factors may improve the recruitment and quality of future trials... - Prescribing patterns of antiparkinsonian agents in EuropeMario Miguel Rosa
Laboratory of Clinical Pharmacology and Therapeutics, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
Mov Disord 25:1053-60. 2010..Costs of medication increased more than did dose consume, implying an increase in the cost of individual patient treatment. Published evidence does not explain the observed differences in the prescribing of APA... - Late-stage Parkinson's disease: the Barcelona and Lisbon cohortMiguel Coelho
Neurological Clinical Research Unit, Instituto de Medicina Molecular, Hospital Santa Maria, Lisbon, Portugal
J Neurol 257:1524-32. 2010..Motor and non-motor non-levodopa responsive problems were frequent and the main cause of disability. Fluctuations and dyskinesias were frequent though not disabling. Dementia is not unavoidable in these very late stages... - Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson diseaseJoaquim J Ferreira
Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon, Portugal
Clin Neuropharmacol 31:2-18. 2008..To investigate the effects of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor, on levodopa pharmacokinetics, COMT activity, and motor fluctuations in Parkinson disease in comparison to placebo and entacapone... - High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in PortugalJoaquim J Ferreira
Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
Mov Disord 22:1194-201. 2007..These data have important implications for the diagnostic work-up and genetic counseling of patients with this disease in Portugal... - Clinical comparability of marketed formulations of botulinum toxinCristina Sampaio
Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal
Mov Disord 19:S129-36. 2004.... - Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosisJoao Costa
Serviço de Neurologia Piso 7, Hospital de Santa Maria, Av Prof Egas Moniz, 1649 035 Lisboa
J Neurol 255:545-50. 2008..Sialorrhea is a disabling problem in bulbaronset amyotrophic lateral sclerosis (ALS). Botulinum toxin (BTX) type A and B have been proposed as alternatives to traditional treatments... 
Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's diseaseMadalena Martins
Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisboa, Portugal
PLoS ONE 6:e25443. 2011..A SNP in ST8SIA4 was also highly associated with PD (p = 6.15×10⁻³) in the meta-dataset. These findings suggest that several miRNAs may act as regulators of both known and novel biological processes leading to idiopathic PD...- The placebo response in studies of acute migraineRicardo Fernandes
Pediatrics Department, Santa Maria Hospital, Lisbon, Portugal
J Pediatr 152:527-33, 533.e1. 2008..To characterize the magnitude of the placebo response in trials of migraine therapy in children and adolescents, and to identify its determinants... - Branded versus generic clopidogrel in cardiovascular diseases: a systematic reviewDaniel Caldeira
Laboratory of Clinical Pharmacology, Faculty of Medicine, University of Lisbon, Lisbon, Portugal Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
J Cardiovasc Pharmacol 61:277-82. 2013..The available evidence is therefore limited and does not support the existence of differences in efficacy or safety between branded and generic clopidogrel... - Late-stage Parkinson diseaseMiguel Coelho
Department of Neuroscience, Hospital Santa Maria, Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
Nat Rev Neurol 8:435-42. 2012..In this article, we review the changing landscape of the later stages of PD, and propose a definition of late-stage PD to designate patients who have progressed beyond the advanced stage... - Evidence-based medicine (EBM) applied to Parkinson's disease treatmentCristina Sampaio
Department of Pharmacology and Therapeutics, Lisbon School of Medicine, Hospital de Santa Maria, 1649 028 Lisbon, Portugal
Parkinsonism Relat Disord 9:7-13. 2002..The concept of management guidelines is presented along with commentaries to the potential variability of recommendations across the world. 3. Limitations of the clinical trials on Parkinson disease treatment so far available... - Treatment options for non-motor symptoms in late-stage Parkinson's diseaseMiguel Coelho
Neurological Clinical Research Unit, Institute of Molecular Medicine, Av Professor Egas Moniz, 1649 028, Lisbon, Portugal
Expert Opin Pharmacother 9:523-35. 2008..Few controlled clinical trials specifically addressed late-stage Parkinson's disease as a target population. There is a need for therapeutic data on the symptoms that most afflict late-stage Parkinson's disease patients... - Pharmacotherapy in Parkinson's disease: case studiesTiago Mestre
Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
Ther Adv Neurol Disord 3:117-26. 2010..The proposed therapeutic alternatives are discussed based on the best data available; that is, treatment guidelines, clinical trial results or observational data... - Current and future therapeutic strategies for Parkinson's diseaseTiago Fleming Outeiro
Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
Curr Pharm Des 15:3968-76. 2009..The therapeutic potential of small molecule modulators of oligomer formation demands further exploration and validation in cellular and animal disease models in order to accelerate human drug development... - Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyDaniel G Healy
Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK
Lancet Neurol 7:583-90. 2008..LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?.. - Limitations of current Parkinson's disease therapyOlivier Rascol
Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France
Ann Neurol 53:S3-12; discussion S12-5. 2003..Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety...